AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie lo Loestrin [legacy through FY21] — International net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, FY2021
14
Period ended Dec 31, 2021
Change on a year earlier
+40.0%
10 in FY2020
History
4 years
Since FY2018
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lo Loestrin [legacy through FY21] — International net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Dec 31, 2021 | 14 | +40.0% | Form 10-K (filed 2022-02-18) ↗ |
| FY2020 | Dec 31, 2020 | 10 | – | Form 10-K (filed 2022-02-18) ↗ |
| FY2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2022-02-18) ↗ |
| FY2018 | Dec 31, 2018 | 0 | – | Form 10-K (filed 2021-02-19) ↗ |
Cite this data
StockData. (2026). AbbVie Lo Loestrin [legacy through FY21] — International net revenues ($M) ($M), annual FY2018–FY2021 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lo_loestrin_intl
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.